Clinical Trial Update: Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of pembrolizumab and cabozantinib in head and neck squamous cell carcinoma reported results, with results posted in Dec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Hypopharyngeal Squamous Cell Carcinoma
• Laryngeal Squamous Cell Carcinoma
• Oral Cavity Squamous Cell Carcinoma
• Oropharyngeal Squamous Cell Carcinoma
• Sinonasal Squamous Cell Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• cabozantinib (cabozantinib)

Snippet

Sponsor: Emory University | Conditions: Metastatic Head and Neck Carcinoma, Paranasal Sinus Squamous Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-12-27